Mark A Dombroski - JoVE Visualize

Showing results (1-10 of 8) with videos related to

Pageof 1

Sort By:

Bioorganic & Medicinal Chemistry Letters|July 26, 2011

Discovery, synthesis and SAR of azinyl- and azolylbenzamides antagonists of the P2X₇ receptorChakrapani Subramanyam, Allen J Duplantier, Mark A Dombroski, et al.

The Journal of Biological Chemistry|March 8, 2003

Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processingRonald E Laliberte, David G Perregaux, Lise R Hoth, et al.

Biopharmaceutics & Drug Disposition|September 1, 2006

Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomesAmit S Kalgutkar, Heather L Hatch, Frederick Kosea, et al.

Bioorganic & Medicinal Chemistry Letters|May 14, 2011

Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535Allen J Duplantier, Mark A Dombroski, Chakrapani Subramanyam, et al.

Bioorganic & Medicinal Chemistry Letters|March 6, 2010

Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesityKevin K-C Liu, Bruce A Lefker, Mark A Dombroski, et al.

Bioorganic & Medicinal Chemistry Letters|March 12, 2004

Benzimidazolone p38 inhibitorsMark A Dombroski, Michael A Letavic, Kim F McClure, et al.

Journal of Medicinal Chemistry|September 2, 2005

Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinaseKim F McClure, Yuriy A Abramov, Ellen R Laird, et al.

Bioorganic & Medicinal Chemistry Letters|June 9, 2006

Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical developmentKim F McClure, Michael A Letavic, Amit S Kalgutkar, et al.

Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:

Pageof 1

Bioorganic & Medicinal Chemistry Letters|July 26, 2011

Discovery, synthesis and SAR of azinyl- and azolylbenzamides antagonists of the P2X₇ receptorChakrapani Subramanyam, Allen J Duplantier, Mark A Dombroski, et al.

The Journal of Biological Chemistry|March 8, 2003

Glutathione s-transferase omega 1-1 is a target of cytokine release inhibitory drugs and may be responsible for their effect on interleukin-1beta posttranslational processingRonald E Laliberte, David G Perregaux, Lise R Hoth, et al.

Biopharmaceutics & Drug Disposition|September 1, 2006

Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomesAmit S Kalgutkar, Heather L Hatch, Frederick Kosea, et al.

Bioorganic & Medicinal Chemistry Letters|May 14, 2011

Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535Allen J Duplantier, Mark A Dombroski, Chakrapani Subramanyam, et al.

Bioorganic & Medicinal Chemistry Letters|March 6, 2010

Orally active and brain permeable proline amides as highly selective 5HT2c agonists for the treatment of obesityKevin K-C Liu, Bruce A Lefker, Mark A Dombroski, et al.

Bioorganic & Medicinal Chemistry Letters|March 12, 2004

Benzimidazolone p38 inhibitorsMark A Dombroski, Michael A Letavic, Kim F McClure, et al.

Journal of Medicinal Chemistry|September 2, 2005

Theoretical and experimental design of atypical kinase inhibitors: application to p38 MAP kinaseKim F McClure, Yuriy A Abramov, Ellen R Laird, et al.

Bioorganic & Medicinal Chemistry Letters|June 9, 2006

Structure-activity relationships of triazolopyridine oxazole p38 inhibitors: identification of candidates for clinical developmentKim F McClure, Michael A Letavic, Amit S Kalgutkar, et al.

Pageof 1